Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension Study

• Main Authors: Caroline J. Stone (Author), Geeta Ahuja (Author), Lais Lopes Almeida Gomes (Author), Joy Poroye (Author), Daniella Forman Faden (Author), Lillian Xie (Author), Rui Feng (Author), Barbara White (Author), Victoria P. Werth (Author)
• Format: Book
• Published: Elsevier, 2025-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Dermatomyositis (DM) is a rare autoimmune condition involving skin manifestations often resistant to standard treatments such as immunosuppressants and antimalarials. Biopsies show elevated inflammatory cells such as CD4+ T cells, dendritic cells, and cytokines. Lenabasum, a selective ca...